nach oben

Breast Cancer Research and Treatment

Erschienen in:

13.12.2017 | Review

Potential biomarkers of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer

verfasst von: Hehui Fang, Doudou Huang, Fang Yang, Xiaoxiang Guan

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Cyclin D/cyclin-dependent kinase 4/6 (CDK4/6) complex inhibitors have recently been proven effective when combined with endocrine therapy in clinical trials. However, the clinical benefit from CDK4/6 inhibitor varied from different patients. In order to optimize the clinical application of CDK4/6 inhibitors, this review focuses on the potential biomarkers applicable to identify patients who will benefit the most from CDK4/6 inhibition.

Methods

We have summarized the clinical trials about addition of CDK4/6 inhibitors to endocrine therapy and reviewed literature currently available on the potential biomarkers in predicting efficacy of CDK4/6 inhibitors. The primary objective was to determine the predictors. The secondary objective was to optimize the combination therapeutics for patients with estrogen receptor (ER)-positive breast cancer.

Results

We reviewed clinical trials on antiestrogen agents combined with the CDK4/6 inhibitor (Palbociclib, Ribociclib, or Abemaciclib) in ER-positive breast cancer. It was confirmed that the addition of CDK4/6 inhibitors was associated with an improved efficacy. More importantly, we discussed potential biomarkers for identifying the subpopulations of breast cancer patients who would derive the greatest benefit from CDK4/6 inhibitors.

Conclusions

We have found that although CDK4/6 inhibitors combined with endocrine therapy were potent, the toxicity and financial burden also increased. To maximize the effect of the combinations and select patients that best response to such combinations, further experiments and trials are expected to confirm these molecules as reliable biomarkers.

Gansler T, Ganz PA, Grant M, Greene FL, Johnstone P, Mahoney M, Newman LA, Oh WK, Thomas CR Jr, Thun MJ, Vickers AJ, Wender RC, Brawley OW (2010) Sixty years of CA: a cancer journal for clinicians. CA Cancer J Clin 60(6):345–350. https://doi.org/10.3322/caac.20088 CrossRefPubMed

Austreid E, Lonning PE, Eikesdal HP (2014) The emergence of targeted drugs in breast cancer to prevent resistance to endocrine treatment and chemotherapy. Expert Opin Pharmacother 15(5):681–700. https://doi.org/10.1517/14656566.2014.885952 CrossRefPubMed

Gillett C, Fantl V, Smith R, Fisher C, Bartek J, Dickson C, Barnes D, Peters G (1994) Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res 54(7):1812–1817PubMed

Ali S, Coombes RC (2002) Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer 2(2):101–112. https://doi.org/10.1038/nrc721 CrossRefPubMed

Alves CL, Elias D, Lyng MB, Bak M, Kirkegaard T, Lykkesfeldt AE, Ditzel HJ (2016) High CDK6 protects cells from fulvestrant-mediated apoptosis and is a predictor of resistance to fulvestrant in estrogen receptor-positive metastatic breast cancer. Clin Cancer Res. https://doi.org/10.1158/1078-0432.CCR-15-1984 PubMed

Vidula N, Rugo HS (2016) Cyclin-dependent kinase 4/6 inhibitors for the treatment of breast cancer: a review of preclinical and clinical data. Clin breast cancer 16(1):8–17. https://doi.org/10.1016/j.clbc.2015.07.005 CrossRefPubMed

Asghar U, Witkiewicz AK, Turner NC, Knudsen ES (2015) The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat rev Drug discov 14(2):130–146. https://doi.org/10.1038/nrd4504 CrossRefPubMedPubMedCentral

Nwabo Kamdje AH, Seke Etet PF, Vecchio L, Muller JM, Krampera M, Lukong KE (2014) Signaling pathways in breast cancer: therapeutic targeting of the microenvironment. Cell Signal 26(12):2843–2856. https://doi.org/10.1016/j.cellsig.2014.07.034 CrossRefPubMed

kinase Sioc-d, 4, 6 by PD 0332991 and associated antitumor activity in human tumor xenografts.Dickson MA (2014) Molecular pathways: CDK4 inhibitors for cancer therapy. Clin Cancer Res 20(13):3379–3383. https://doi.org/10.1158/1078-0432.CCR-13-1551 CrossRef

10.

Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E, Albassam M, Zheng X, Leopold WR, Pryer NK, Toogood PL (2004) Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther 3(11):1427–1438PubMed

11.

Cicenas J, Valius M (2011) The CDK inhibitors in cancer research and therapy. J Cancer Res Clin Oncol 137(10):1409–1418. https://doi.org/10.1007/s00432-011-1039-4 CrossRefPubMed

12.

Zhang W, Xu J, Shi Y, Sun Q, Zhang Q, Guan X (2015) The novel role of miRNAs for tamoxifen resistance in human breast cancer. Cell Mol Life Sci 72(13):2575–2584. https://doi.org/10.1007/s00018-015-1887-1 CrossRefPubMed

13.

Schiavon G, Smith IE (2013) Endocrine therapy for advanced/metastatic breast cancer. Hematol/oncol clin N Am 27(4):715–736. https://doi.org/10.1016/j.hoc.2013.05.004 CrossRef

14.

Kwapisz D (2017) Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib. Breast Cancer Res Treat. https://doi.org/10.1007/s10549-017-4385-3 PubMed

15.

Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, Ettl J, Patel R, Pinter T, Schmidt M, Shparyk Y, Thummala AR, Voytko NL, Fowst C, Huang X, Kim ST, Randolph S, Slamon DJ (2015) The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol 16(1):25–35. https://doi.org/10.1016/S1470-2045(14)71159-3 CrossRefPubMed

16.

Beaver JA, Amiri-Kordestani L, Charlab R, Chen W, Palmby T, Tilley A, Zirkelbach JF, Yu J, Liu Q, Zhao L, Crich J, Chen XH, Hughes M, Bloomquist E, Tang S, Sridhara R, Kluetz PG, Kim G, Ibrahim A, Pazdur R, Cortazar P (2015) FDA approval: palbociclib for the treatment of postmenopausal patients with estrogen receptor-positive, HER2-negative metastatic breast cancer. Clin Cancer Res 21(21):4760–4766. https://doi.org/10.1158/1078-0432.CCR-15-1185 CrossRefPubMed

17.

Bartsch R, Bergen E (2016) ASCO 2016: highlights in breast cancer. Memo 9(4):211–214. https://doi.org/10.1007/s12254-016-0300-6 CrossRefPubMedPubMedCentral

18.

Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im SA, Masuda N, Colleoni M, DeMichele A, Loi S, Verma S, Iwata H, Harbeck N, Zhang K, Theall KP, Jiang YQ, Bartlett CH, Koehler M, Slamon D (2016) Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol 17(4):425–439. https://doi.org/10.1016/S1470-2045(15)00613-0 CrossRefPubMed

19.

Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, Campone M, Blackwell KL, Andre F, Winer EP, Janni W, Verma S, Conte P, Arteaga CL, Cameron DA, Petrakova K, Hart LL, Villanueva C, Chan A, Jakobsen E, Nusch A, Burdaeva O, Grischke EM, Alba E, Wist E, Marschner N, Favret AM, Yardley D, Bachelot T, Tseng LM, Blau S, Xuan F, Souami F, Miller M, Germa C, Hirawat S, O’Shaughnessy J (2016) Ribociclib as first-line therapy for hr-positive, advanced breast cancer. N Engl J Med 375(18):1738–1748. https://doi.org/10.1056/NEJMoa1609709 CrossRefPubMed

20.

Fasching PA, Jerusalem G, Pivot X, Martin M, De Laurentiis M, Blackwell K, Esteva FJ, Paquet-Luzy T, Tang Z, Lorenc KR, Slamon DJ (2016) Phase III study of ribociclib (LEE011) in combination with fulvestrant for the treatment of postmenopausal patients (pts) with hormone receptor-positive (HR +), HER2-negative (HER2-) advanced breast cancer (aBC) who have received no or only one line of prior endocrine treatment: MONALEESA-3. Cancer Res. https://doi.org/10.1158/1538-7445.SABCS15-OT2-01-02

21.

Dickler MN, Tolaney SM, Rugo HS, Cortes J, Dieras V, Patt D, Wildiers H, Hudis CA, O’Shaughnessy J, Zamora E, Yardley DA, Frenzel M, Koustenis A, Baselga J (2017) MONARCH 1, a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR +/HER2- metastatic breast cancer. Clin Cancer Res. https://doi.org/10.1158/1078-0432.CCR-17-0754

22.

Sledge GW Jr, Toi M, Neven P, Sohn J, Inoue K, Pivot X, Burdaeva O, Okera M, Masuda N, Kaufman PA, Koh H, Grischke EM, Frenzel M, Lin Y, Barriga S, Smith IC, Bourayou N, Llombart-Cussac A (2017) MONARCH 2: abemaciclib in combination with fulvestrant in women with HR +/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol. https://doi.org/10.1200/JCO.2017.73.7585

23.

Turner NC, Huang Bartlett C, Cristofanilli M (2015) Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med 373(17):1672–1673. https://doi.org/10.1056/NEJMc1510345 CrossRefPubMed

24.

Spring LM, Zangardi ML, Moy B, Bardia A (2017) Clinical management of potential toxicities and drug interactions related to cyclin-dependent kinase 4/6 inhibitors in breast cancer: practical considerations and recommendations. Oncologist 22(9):1039–1048. https://doi.org/10.1634/theoncologist.2017-0142 CrossRefPubMedPubMedCentral

25.

Zafar SY, Peppercorn JM, Schrag D, Taylor DH, Goetzinger AM, Zhong X, Abernethy AP (2013) The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient’s experience. Oncologist 18(4):381–390. https://doi.org/10.1634/theoncologist.2012-0279 CrossRefPubMedPubMedCentral

26.

Robertson JFR, Bondarenko IM, Trishkina E, Dvorkin M, Panasci L, Manikhas A, Shparyk Y, Cardona-Huerta S, Cheung KL, Philco-Salas MJ, Ruiz-Borrego M, Shao Z, Noguchi S, Rowbottom J, Stuart M, Grinsted LM, Fazal M, Ellis MJ (2016) Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. Lancet 388(10063):2997–3005. https://doi.org/10.1016/S0140-6736(16)32389-3 CrossRefPubMed

27.

Patnaik A, Rosen LS, Tolaney SM, Tolcher AW, Goldman JW, Gandhi L, Papadopoulos KP, Beeram M, Rasco DW, Hilton JF, Nasir A, Beckmann RP, Schade AE, Fulford AD, Nguyen TS, Martinez R, Kulanthaivel P, Li LQ, Frenzel M, Cronier DM, Chan EM, Flaherty KT, Wen PY, Shapiro GI (2016) Efficacy and safety of abemaciclib, an inhibitor of CDK4 and CDK6, for patients with breast cancer, non-small cell lung cancer, and other solid tumors. Cancer Discov 6(7):740–753. https://doi.org/10.1158/2159-8290.CD-16-0095 CrossRefPubMed

28.

Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K, Harbeck N, Lipatov ON, Walshe JM, Moulder S, Gauthier E, Lu DRR, Randolph S, Dieras V, Slamon DJ (2016) Palbociclib and letrozole in advanced breast cancer. N Engl J Med 375(20):1925–1936. https://doi.org/10.1056/Nejmoa1607303 CrossRefPubMed

29.

Asghar US, Barr AR, Cutts R, Beaney M, Babina I, Sampath D, Giltnane J, Lacap JA, Crocker L, Young A, Pearson A, Herrera-Abreu MT, Bakal C, Turner NC (2017) Single-cell dynamics determines response to CDK4/6 inhibition in triple-negative breast cancer. Clin Cancer Res 23(18):5561–5572. https://doi.org/10.1158/1078-0432.CCR-17-0369 CrossRefPubMed

30.

Spencer SL, Cappell SD, Tsai FC, Overton KW, Wang CL, Meyer T (2013) The proliferation-quiescence decision is controlled by a bifurcation in CDK2 activity at mitotic exit. Cell 155(2):369–383. https://doi.org/10.1016/j.cell.2013.08.062 CrossRefPubMedPubMedCentral

31.

DeMichele A, Clark AS, Tan KS, Heitjan DF, Gramlich K, Gallagher M, Lal P, Feldman M, Zhang P, Colameco C, Lewis D, Langer M, Goodman N, Domchek S, Gogineni K, Rosen M, Fox K, O’Dwyer P (2015) CDK 4/6 inhibitor palbociclib (PD0332991) in Rb + advanced breast cancer: phase II activity, safety, and predictive biomarker assessment. Clin Cancer Res 21(5):995–1001. https://doi.org/10.1158/1078-0432.CCR-14-2258 CrossRefPubMed

32.

Arnedos M, Cheaib B, Bayar MA, Michiels S, Scott V, Adam J, Leroux-Kozal V, Marty V, Mazouni C, Sarfati B, Bieche I, Gentien D, Delaloge S, Lacroix-Triki M, Andre F (2016) Anti-proliferative response and predictive biomarkers to palbociclib in early breast cancer: the preoperative palbociclib (POP) randomized trial. Cancer Res 76:615CrossRef

33.

Finn R, Jiang Y, Rugo H, Moulder SL, Im SA, Gelmon KA, Dieras V, Martin M, Joy AA, Toi M, Gauthier E, Lu DR, Bartlett CH, Slamon D (2016) Biomarker analyses from the phase 3 PALOMA-2 trial of palbociclib (P) with letrozole (L) compared with placebo (PLB) plus L in postmenopausal women with ER +/HER2-advanced breast cancer (ABC). Ann Oncol. https://doi.org/10.1093/annonc/mdw435.5

34.

Raspe E, Coulonval K, Pita JM, Paternot S, Rothe F, Twyffels L, Brohee S, Craciun L, Larsimont D, Kruys V, Sandras F, Salmon I, Van Laere S, Piccart M, Ignatiadis M, Sotiriou C, Roger PP (2017) CDK4 phosphorylation status and a linked gene expression profile predict sensitivity to palbociclib. EMBO mol med. https://doi.org/10.15252/emmm.201607084 PubMedPubMedCentral

35.

Alves CL, Elias D, Lyng M, Bak M, Kirkegaard T, Lykkesfeldt AE, Ditzel HJ (2016) High CDK6 protects cells from fulvestrant-mediated apoptosis and is a predictor of resistance to fulvestrant in estrogen receptor-positive metastatic breast cancer. Clin Cancer Res 22(22):5514–5526. https://doi.org/10.1158/1078-0432.CCR-15-1984 CrossRefPubMed

36.

Wang H, Nicolay BN, Chick JM, Gao X, Geng Y, Ren H, Gao H, Yang G, Williams JA, Suski JM, Keibler MA, Sicinska E, Gerdemann U, Haining WN, Roberts TM, Polyak K, Gygi SP, Dyson NJ, Sicinski P (2017) The metabolic function of cyclin D3-CDK6 kinase in cancer cell survival. Nature 546(7658):426–430. https://doi.org/10.1038/nature22797 CrossRefPubMedPubMedCentral

37.

Dean JL, Thangavel C, McClendon AK, Reed CA, Knudsen ES (2010) Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure. Oncogene 29(28):4018–4032. https://doi.org/10.1038/onc.2010.154 CrossRefPubMed

38.

Dulic V, Lees E, Reed SI (1992) Association of human cyclin E with a periodic G1-S phase protein kinase. Science 257(5078):1958–1961CrossRefPubMed

39.

Herrera-Abreu MT, Palafox M, Asghar U, Rivas MA, Cutts RJ, Garcia-Murillas I, Pearson A, Guzman M, Rodriguez O, Grueso J, Bellet M, Cortes J, Elliott R, Pancholi S, Baselga J, Dowsett M, Martin LA, Turner NC, Serra V (2016) Early adaptation and acquired resistance to CDK4/6 inhibition in estrogen receptor-positive breast cancer. Cancer Res 76(8):2301–2313. https://doi.org/10.1158/0008-5472.CAN-15-0728 CrossRefPubMedPubMedCentral

40.

Karakas C, Biernacka A, Bui T, Sahin AA, Yi M, Akli S, Schafer J, Alexander A, Adjapong O, Hunt KK, Keyomarsi K (2016) Cytoplasmic cyclin e and phospho-cyclin-dependent kinase 2 are biomarkers of aggressive breast cancer. Am J Pathol 186(7):1900–1912. https://doi.org/10.1016/j.ajpath.2016.02.024 CrossRefPubMedPubMedCentral

41.

Hunt KK, Karakas C, Ha MJ, Biernacka A, Yi M, Sahin AA, Adjapong O, Hortobagyi GN, Bondy ML, Thompson PA, Cheung KL, Ellis IO, Bacus S, Symmans WF, Do KA, Keyomarsi K (2017) Cytoplasmic cyclin e predicts recurrence in patients with breast cancer. Clin Cancer Res 23(12):2991–3002. https://doi.org/10.1158/1078-0432.CCR-16-2217 CrossRefPubMed

42.

Vijayaraghavan S, Karakas C, Doostan I, Chen X, Bui T, Yi M, Raghavendra AS, Zhao Y, Bashour SI, Ibrahim NK, Karuturi M, Wang J, Winkler JD, Amaravadi RK, Hunt KK, Tripathy D, Keyomarsi K (2017) CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers. Nature commun 8:15916. https://doi.org/10.1038/ncomms15916 CrossRef

43.

Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, Desai AJ, Ginther C, Atefi M, Chen I, Fowst C, Los G, Slamon DJ (2009) PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. https://doi.org/10.1186/Bcr2419 PubMedPubMedCentral

44.

Malorni L, Piazza S, Ciani Y, Guarducci C, Bonechi M, Biagioni C, Hart CD, Verardo R, Di Leo A, Migliaccio I (2016) A gene expression signature of retinoblastoma loss-of-function is a predictive biomarker of resistance to palbociclib in breast cancer cell lines and is prognostic in patients with ER positive early breast cancer. Oncotarget 7(42):68012–68022. https://doi.org/10.18632/oncotarget.12010 CrossRefPubMedPubMedCentral

45.

McClendon AK, Dean JL, Rivadeneira DB, Yu JE, Reed CA, Gao E, Farber JL, Force T, Koch WJ, Knudsen ES (2012) CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy. Cell Cycle 11(14):2747–2755. https://doi.org/10.4161/cc.21127 CrossRefPubMedPubMedCentral

46.

Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA (2011) Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121(7):2750–2767. https://doi.org/10.1172/JCI45014 CrossRefPubMedPubMedCentral

47.

Asghar U, Herrera-Abreu MT, Cutts R, Babina I, Pearson A, Turner NC (2015) Identification of subtypes of triple negative breast cancer (TNBC) that are sensitive to CDK4/6 inhibition. J Clin Oncol 33(15):11098

48.

Dean JL, McClendon AK, Hickey TE, Butler LM, Tilley WD, Witkiewicz AK, Knudsen ES (2012) Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors. Cell Cycle 11(14):2756–2761. https://doi.org/10.4161/cc.21195 CrossRefPubMedPubMedCentral

49.

Witkiewicz AK, Cox D, Knudsen ES (2014) CDK4/6 inhibition provides a potent adjunct to Her2-targeted therapies in preclinical breast cancer models. Genes cancer 5(7–8):261–272. https://doi.org/10.18632/genesandcancer.24 PubMedPubMedCentral

50.

Rader J, Russell MR, Hart LS, Nakazawa MS, Belcastro LT, Martinez D, Li YM, Carpenter EL, Attiyeh EF, Diskin SJ, Kim S, Parasuraman S, Caponigro G, Schnepp RW, Wood AC, Pawel B, Cole KA, Maris JM (2013) Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma. Clin Cancer Res 19(22):6173–6182. https://doi.org/10.1158/1078-0432.CCR-13-1675 CrossRefPubMed

51.

Goel S, Wang Q, Watt AC, Tolaney SM, Dillon DA, Li W, Ramm S, Palmer AC, Yuzugullu H, Varadan V, Tuck D, Harris LN, Wong KK, Liu XS, Sicinski P, Winer EP, Krop IE, Zhao JJ (2016) Overcoming therapeutic resistance in HER2-positive breast cancers with cdk4/6 inhibitors. Cancer Cell 29(3):255–269. https://doi.org/10.1016/j.ccell.2016.02.006 CrossRefPubMedPubMedCentral

52.

Gelbert LM, Cai S, Lin X, Sanchez-Martinez C, Del Prado M, Lallena MJ, Torres R, Ajamie RT, Wishart GN, Flack RS, Neubauer BL, Young J, Chan EM, Iversen P, Cronier D, Kreklau E, de Dios A (2014) Preclinical characterization of the CDK4/6 inhibitor LY2835219: in vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine. Investig new drugs 32(5):825–837. https://doi.org/10.1007/s10637-014-0120-7 CrossRef

53.

Ma CX, Gao F, Luo J, Northfelt DW, Goetz M, Forero A, Hoog J, Naughton M, Ademuyiwa F, Suresh R, Anderson KS, Margenthaler J, Aft R, Hobday T, Moynihan T, Gillanders W, Cyr A, Eberlein TJ, Hieken T, Krontiras H, Guo Z, Lee MV, Spies NC, Skidmore ZL, Griffith OL, Griffith M, Thomas S, Bumb C, Vij K, Bartlett CH, Koehler M, Al-Kateb H, Sanati S, Ellis MJ (2017) NeoPalAna: neoadjuvant palbociclib, a cyclin-dependent kinase 4/6 Inhibitor, and anastrozole for clinical stage 2 or 3 estrogen receptor-positive breast cancer. Clin Cancer Res 23(15):4055–4065. https://doi.org/10.1158/1078-0432.CCR-16-3206 CrossRefPubMedPubMedCentral

54.

Fribbens C, O’Leary B, Kilburn L, Hrebien S, Garcia-Murillas I, Beaney M, Cristofanilli M, Andre F, Loi S, Loibl S, Jiang J, Bartlett CH, Koehler M, Dowsett M, Bliss JM, Johnston SR, Turner NC (2016) Plasma ESR1 mutations and the treatment of estrogen receptor-positive advanced breast cancer. J Clin Oncol 34(25):2961–2968. https://doi.org/10.1200/JCO.2016.67.3061 CrossRefPubMed

55.

Miller TW, Rexer BN, Garrett JT, Arteaga CL (2011) Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer. Breast Cancer Res 13(6):224. https://doi.org/10.1186/bcr3039 CrossRefPubMedPubMedCentral

56.

Huang D, Yang F, Wang Y (1868) Guan X (2017) Mechanisms of resistance to selective estrogen receptor down-regulator in metastatic breast cancer. Biochem Biophys Acta 1:148–156. https://doi.org/10.1016/j.bbcan.2017.03.008

57.

58.

Bashour SI, Doostan I, Keyomarsi K, Valero V, Ueno NT, Brown PH, Litton JK, Koenig KB, Karuturi M, Abouharb S, Tripathy D, Moulder-Thompson SL, Ibrahim NK (2017) Rapid breast cancer disease progression following cyclin dependent kinase 4 and 6 inhibitor discontinuation. J Cancer 8(11):2004–2009. https://doi.org/10.7150/jca.18196 CrossRefPubMedPubMedCentral

59.

Jansen VM, Bhola NE, Bauer JA, Formisano L, Lee KM, Hutchinson KE, Witkiewicz AK, Moore PD, Estrada MV, Sanchez V, Ericsson PG, Sanders ME, Pohlmann PR, Pishvaian MJ, Riddle DA, Dugger TC, Wei W, Knudsen ES, Arteaga CL (2017) Kinome-wide rna interference screen reveals a role for PDK1 in acquired resistance to CDK4/6 inhibition in ER-positive breast cancer. Cancer Res 77(9):2488–2499. https://doi.org/10.1158/0008-5472.CAN-16-2653 CrossRefPubMed

60.

Yang C, Li Z, Bhatt T, Dickler M, Giri D, Scaltriti M, Baselga J, Rosen N, Chandarlapaty S (2017) Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence. Oncogene 36(16):2255–2264. https://doi.org/10.1038/onc.2016.379 CrossRefPubMed

Titel: Potential biomarkers of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer
verfasst von: Hehui Fang
Doudou Huang
Fang Yang
Xiaoxiang Guan
Publikationsdatum: 13.12.2017
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 2/2018
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-017-4612-y

Neu im Fachgebiet Onkologie

23.04.2024 | Medikamente in Schwangerschaft und Stillzeit | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Potential biomarkers of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer

Abstract

Purpose

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2018

Long-term safety and survival outcomes from the Scandinavian Breast Group 2004-1 randomized phase II trial of tailored dose-dense adjuvant chemotherapy for early breast cancer

Effects of physical exercise on markers of inflammation in breast cancer patients during adjuvant chemotherapy

CD14+ HLA-DR−/low MDSCs are elevated in the periphery of early-stage breast cancer patients and suppress autologous T cell proliferation

Relevant factors for the optimal duration of extended endocrine therapy in early breast cancer

Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy

Efficacy of palbociclib plus fulvestrant after everolimus in hormone receptor-positive metastatic breast cancer

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie